Eli Lilly's triple-hormone drug retatrutide ↗ lowered blood sugar and cut weight harder than almost any diabetes drug on record in its first big Phase 3 trial. It also logged a small number of heart events that placebo did not. Three patients on the drug had a major cardiac event. None on placebo did.
The efficacy was the headline at the American Diabetes Association meeting in New Orleans on Saturday. The cardiac numbers were the asterisk, and they are the part worth slowing down on.
What the trial found
TRANSCEND-T2D-1, published the same day in The Lancet ↗00967-0), tested retatrutide in 537 adults with recent-onset type 2 diabetes, on average about two and a half years in, who were managing on diet and exercise alone. Over 40 weeks they got a once-weekly injection at 4, 9, or 12 mg, or a placebo shot.
The glucose results were the kind trials rarely show. A1C, the three-month average blood-sugar measure, fell by as much as 2.0 percentage points from a starting point near 7.9 percent. As many as 46 percent of patients on the drug reached a normal, non-diabetic A1C, below the threshold that defines diabetes at all. Weight came down up to 16.8 percent, roughly 37 pounds, at the top dose, and was still falling at week 40. Blood pressure, triglycerides, and waist size moved with it.
For a once-weekly shot in people who had been on no medication, pushing nearly half of them back out of the diabetes range is a number clinicians will be repeating for a while.
The heart-event imbalance
Then the safety table. Across the 403 patients who received retatrutide, seven had an arrhythmia, an irregular or abnormal heartbeat, and three had a major adverse cardiovascular event, meaning a heart attack, a stroke, or death from a cardiac cause. In the placebo group, none did.
STAT reported ↗ the imbalance from the floor of the meeting on Saturday. The caveat came with it: the event counts are too small to draw a conclusion from. Three events against zero, in a 40-week trial of a few hundred people, can be noise. It can also be the first faint edge of something real. A trial this size cannot tell the two apart, and the honest read is that nobody yet knows which it is.
What keeps it from being dismissible is the mechanism. Retatrutide is not a semaglutide ↗ or a tirzepatide ↗. Those drugs hit the GLP-1 receptor, or GLP-1 plus GIP, the gut-hormone pathways that blunt appetite and prompt insulin. Retatrutide adds a third target, the glucagon receptor ↗, the switch that ramps up how much energy the body burns. That extra arm is a large part of why the weight numbers run higher than anything in the class. It also nudges up heart rate and metabolic rate, which is exactly the kind of physiology that, in principle, could surface as an arrhythmia. The GLP-1 and GLP-1 plus GIP drugs have not shown a cardiac signal like this. The glucagon component is the obvious thing that is different.
Why the answer is still a year out
The trial that can actually settle it is already running. TRIUMPH-OUTCOMES is Lilly's dedicated cardiovascular outcomes study, built large enough and long enough to count heart events as its main job rather than as a line in a safety table. It reads out in 2027. Until then, every retatrutide cardiac number, including these three, is a watch item, not a verdict.
That gap matters because retatrutide is on track to be the most potent metabolic drug yet submitted to regulators, and the obesity field has spent two years celebrating its weight numbers. The diabetes data published Saturday earns the celebration. The three heart events earn the wait. Both can be true, and a drug this strong deserves to have both reported at the same volume.
The earlier topline from this same trial, disclosed on Lilly's spring earnings call, carried the glucose and weight figures but not the cardiac breakdown. The full publication is the first time the heart-event counts are on the page. That is the news.